Veracyte (VCYT) announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte management to meet with Craig-Hallum
- Cautious Outlook on Veracyte: Sell Rating Amid Market Uncertainties and Valuation Concerns
- Veracyte price target lowered to $28 from $29 at Morgan Stanley
- Veracyte’s Strong Clinical Evidence and Market Growth Justify Buy Rating
- Veracyte Inc’s Earnings Call Highlights Robust Growth and Strategic Milestones